No Data
H.C. Wainwright Maintains Scholar Rock(SRRK.US) With Buy Rating, Maintains Target Price $30
Scholar Rock Provides Preclinical Data for Its Investigational Obesity Candidate
Express News | Scholar Rock Has Dosed The First Participants In The Phase 2 EMBRAZE Proof-of-concept Trial Of Apitegromab To Preserve Lean Muscle Mass In Individuals Living With Obesity And On Background Therapy Of A GLP-1 Receptor Agonist
Express News | Scholar Rock Holding Corp: First Participants Were Dosed in Phase 2 Embraze Proof-of-Concept Trial
Express News | Scholar Rock Announces New Srk-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal
Have Insiders Sold Scholar Rock Holding Shares Recently?